Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
3
×
Tags
life sciences
national blog main
san francisco blog main
3
×
biotech
clinical trials
fda
san francisco
san francisco top stories
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bluebird bio
boston
boston blog main
boston top stories
cannabidiol
deals
dravet syndrome
drugs
duchenne muscular dystrophy
dyne therapeutics
epidiolex
facioscapulohumeral muscular dystrophy
fen-phen
fenfluramine
food and drug administration
gene therapy
gw pharmaceuticals
joshua brumm
kaleido biosciences
lennox-gastaut syndrome
medical device
muscular dystrophy
myotonic dystrophy type 1
national top stories
new york blog main
pulmonary arterial hypertension
raleigh-durham blog main
rare disease drugs
What
drug
rare
3
×
ago
data
therapeutics
approved
battle
biotechs
building
cannabis
considering
deal
derivative
developer
disease
diseases
dyne
early
epilepsy
established
expected
experimental
eyes
fda
firm
form
genetic
gw
gw’s
having
humans
ipo
ipos
long
lung
marijuana
market
medicine
medicines
momentum
Language
unset
Current search:
rare
×
photo
×
" san francisco blog main "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed
